Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250355) titled 'TO-211 Phase III Clinical Study' on Sept. 10.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, active control, single assignment, diagnostic purpose
Primary Sponsor: Kikuchi Masayo
Condition:
Allergic diseases caused by Alternaria
Intervention:
TO-211, comparater (Allergen Scratch Extract "Torii" Alternaria), negative control and positive control will be administered one drop at a time to the flexor side of the forearm of the subject. These drugs are not for treatment purposes but are used for allergy diagnosis.
Recruitment Status: Recruiting
Phase: 3
Date of Fir...